EICHOR
● Active Not Recruiting
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
Condition: Arteriosclerosis · Hypercholesterolaemia · Sponsor: Merck Sharp & Dohme LLC
About this study
This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk. The primary objective is to evaluate the efficacy of enlicitide decanoate compared with placebo in increasing the time to the first occurrence of major adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb ischemia or major amputation, or urgent arterial revascularization.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (669)
| Advanced Cardiovascular - Alexander City ( Site 0156) | Alexander City, Alabama, United States | — |
| Central Research Associates ( Site 0118) | Birmingham, Alabama, United States | — |
| St. Vincent's Birmingham Hospital ( Site 0181) | Birmingham, Alabama, United States | — |
| Central Alabama Research ( Site 0109) | Birmingham, Alabama, United States | — |
| Alliance for Multispecialty Research, LLC ( Site 0076) | Daphne, Alabama, United States | — |
| G&L Research ( Site 0042) | Foley, Alabama, United States | — |
| NextStage Clinical Research - Phoenix - (01) ( Site 0191) | Glendale, Arizona, United States | — |
| Synexus Clinical Research US, Inc.-Synexus Clinical Research US, Inc - Central Phoenix ( Site 0066) | Phoenix, Arizona, United States | — |
| Medical Investigations Inc. ( Site 0188) | Little Rock, Arkansas, United States | — |
| National Heart Institute-Research ( Site 0077) | Beverly Hills, California, United States | — |
| UCSD - Altman Clinical and Translational Research Institute (ACTRI) ( Site 0130) | La Jolla, California, United States | — |
| Chemidox Clinical Trials ( Site 0145) | Lancaster, California, United States | — |
+ 657 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.